

# Matthew R Weir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1830663/publications.pdf>

Version: 2024-02-01

510  
papers

25,900  
citations

5574

82  
h-index

9861

141  
g-index

516  
all docs

516  
docs citations

516  
times ranked

20387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the <sc>CANVAS</sc> Program and <sc>CREDENCE</sc> trial. Diabetes, Obesity and Metabolism, 2022, 24, 12-20.	4.4	1
2	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the <sc>DIAMOND</sc> trial. European Journal of Heart Failure, 2022, 24, 230-238.	7.1	32
3	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. JAMA Cardiology, 2022, 7, 549.	6.1	14
4	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2022, 79, 311-327.	1.9	21
5	Emergency Department/Urgent Care as Usual Source of Care and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort Study. Kidney Medicine, 2022, 4, 100424.	2.0	2
6	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
7	Prediction of Incident Heart Failure in CKD: The CRIC Study. Kidney International Reports, 2022, 7, 708-719.	0.8	5
8	Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD. Kidney360, 2022, 3, 859-871.	2.1	6
9	Kidney transplant candidacy evaluation and waitlisting practices in the United States and their association with access to transplantation. American Journal of Transplantation, 2022, 22, 1624-1636.	4.7	7
10	Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney International, 2022, 101, 793-803.	5.2	55
11	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8
12	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. Digital Health, 2022, 8, 205520762211079.	1.8	4
13	Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. American Journal of Nephrology, 2022, 53, 513-515.	3.1	3
14	Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. Nephrology Dialysis Transplantation, 2021, 37, 139-147.	0.7	18
15	Clinical Management of Hyperkalemia. Mayo Clinic Proceedings, 2021, 96, 744-762.	3.0	87
16	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. Hypertension, 2021, 77, 72-81.	2.7	13
17	Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2021, 77, 235-244.	1.9	68
18	Characterization and implications of the initial estimated glomerular filtration rate -dip- upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	5.2	111

#	ARTICLE	IF	CITATIONS
19	Risk Factors for CKD Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 648-659.	4.5	65
20	A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 469-478.	6.1	2
21	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 99, 34-47.	5.2	195
22	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. CKJ: Clinical Kidney Journal, 2021, 14, 1396-1402.	2.9	18
23	Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. American Journal of Nephrology, 2021, 52, 450-466.	3.1	38
24	Causes of Renal Allograft Injury in Recipients With Normal Donor-derived Cell-free DNA. Transplantation Direct, 2021, 7, e679.	1.6	8
25	The Importance of Bringing Transplantation Tolerance to the Clinic. Transplantation, 2021, 105, 935-940.	1.0	3
26	BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR RADIOFREQUENCY RENAL DENERVATION IN UNTREATED HYPERTENSION. Journal of Hypertension, 2021, 39, e10.	0.5	0
27	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. Drugs - Real World Outcomes, 2021, 8, 315-323.	1.6	13
28	FC 024SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALAEMIA IN PATIENTS WITH STAGE 1-3A OR STAGE 3B-5 CHRONIC KIDNEY DISEASE: POOLED ANALYSIS OF THE AMETHYST-DN, OPAL-HK AND TOURMALINE TRIALS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
29	FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
30	Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. Clinical Transplantation, 2021, 35, e14326.	1.6	4
31	Patients' and family members' perspectives on arrhythmias and sudden death in dialysis: the HeartLink focus groups pilot study. BMC Nephrology, 2021, 22, 199.	1.8	1
32	Real-World Diagnosis and Treatment of Diabetic Kidney Disease. Advances in Therapy, 2021, 38, 4425-4441.	2.9	13
33	Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108029.	2.3	6
34	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. Kidney360, 2021, 2, 1998-2009.	2.1	12
35	Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. Transplantation, 2021, 105, 443-450.	1.0	12
36	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. Diabetes Therapy, 2021, 12, 3167-3186.	2.5	3

#	ARTICLE	IF	CITATIONS
37	Hyperkalemia management in the emergency department: An expert panel consensus. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12572.	0.7	11
38	Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1185-1201.	2.9	5
39	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	5.2	260
40	Hematologic and Infectious Complications of Chronic Kidney Disease. , 2020, , 477-502.		1
41	Extravascular Lung Water Assessment by Ultrasound to Guide Dry Weight Changes: Ready for Prime Time?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 1-3.	1.9	144
42	APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. <i>Kidney International Reports</i> , 2020, 5, 278-288.	0.8	62
43	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2609-2621.	6.1	33
44	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , 2020, 98, 168-175.	5.2	34
45	An evidence-based appraisal of complementary and alternative medicine strategies for the management of hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1412-1419.	0.5	2
46	Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm. <i>Kidney360</i> , 2020, 1, 1146-1154.	2.1	3
47	Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2020, 6, e568.	1.6	18
48	Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease". <i>American Heart Journal</i> , 2020, 223, 111-112.	2.7	1
49	Should Renin-Angiotensin System Blockade Be Avoided in Patients With Declining Kidney Function?. <i>American Journal of Kidney Diseases</i> , 2020, 76, 739-741.	1.9	2
50	Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020, 1, 623-630.	2.1	10
51	LB005 KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE "EGFR DIP"™ IN EMPA-REG OUTCOME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
52	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	2.8	94
53	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 861-876.	5.2	126
54	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	3.1	9

#	ARTICLE	IF	CITATIONS
55	High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. <i>American Journal of Transplantation</i> , 2020, 20, 2491-2498.	4.7	87
56	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , 2020, 6, FSO441.	1.9	8
57	The REDUCE HTN: REINFORCE. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 461-470.	2.9	53
58	The authors reply. <i>Kidney International</i> , 2020, 97, 213-214.	5.2	0
59	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. <i>American Heart Journal</i> , 2020, 223, 3-11.	2.7	38
60	Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 184-193.	1.9	35
61	Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients Without Diabetes: Does Age Matter?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 294-296.	1.9	1
62	Reserpine: A New Consideration of an Old Drug for Refractory Hypertension. <i>American Journal of Hypertension</i> , 2020, 33, 708-710.	2.0	8
63	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 455-464.	4.5	13
64	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 29013-29024.	7.1	46
65	132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. <i>Diabetes</i> , 2020, 69, 132-LB.	0.6	0
66	Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease—A Report from the Chronic Renal Insufficiency Cohort Study. <i>Kidney360</i> , 2020, 1, 810-818.	2.1	2
67	Recognition and Management of a Less Common Cause of Chronic Kidney Disease: Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Family Practice</i> , 2020, 69, S57-S62.	0.2	0
68	Primary care of the kidney transplant recipient. , 2019, , 424-428.		0
69	Immunosuppression. , 2019, , 405-409.		0
70	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2019, 73, 51-61.	1.9	30
71	Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. <i>Kidney International Reports</i> , 2019, 4, 1555-1567.	0.8	30
72	Global Health Training Opportunities in North American Nephrology Fellowships. <i>Kidney International Reports</i> , 2019, 4, 904-907.	0.8	1

#	ARTICLE	IF	CITATIONS
73	SP049INFLAMMATION AND APPARENT TREATMENT RESISTANT HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
74	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases, 2019, 74, 771-781.	1.9	11
75	Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1493-1499.	4.5	39
76	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. American Journal of Kidney Diseases, 2019, 73, 827-836.	1.9	43
77	Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. Journal of the American College of Cardiology, 2019, 73, 2691-2700.	2.8	65
78	Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. Postgraduate Medicine, 2019, 131, 367-375.	2.0	3
79	Therapeutic Potential of Newer Drugs for Treating Hyperkalemia. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 787-788.	4.5	2
80	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. Journal of Diabetes, 2019, 11, 619-622.	1.8	4
81	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
82	Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2019, 8, e011013.	3.7	13
83	Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International, 2019, 96, 489-504.	5.2	77
84	Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases, 2019, 74, 120-131.	1.9	277
85	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American Journal of Kidney Diseases, 2019, 73, 437-458.	1.9	24
86	Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease. Hypertension, 2019, 73, 785-793.	2.7	34
87	Blood Pressure and Living Kidney Donors: A Clinical Perspective. Transplantation Direct, 2019, 5, e488.	1.6	8
88	Chronic Kidney Disease in the Primary Care Setting: Cardiovascular Disease Risk and Management. Contemporary Cardiology, 2019, , 179-216.	0.1	0
89	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. Journal of Cardiac Failure, 2019, 25, 436-447.	1.7	13
90	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. European Heart Journal, 2018, 39, 2314-2325.	2.2	186

#	ARTICLE	IF	CITATIONS
91	Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 585-595.	4.5	24
92	Hyperkalemia in the Hypertensive Patient. <i>Current Cardiology Reports</i> , 2018, 20, 12.	2.9	7
93	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 665-675.	2.3	23
94	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality. <i>Hypertension</i> , 2018, 71, 1101-1107.	2.7	99
95	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	2.8	50
96	Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Sleep Research</i> , 2018, 27, 283-291.	3.2	26
97	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018, 131, 165-172.	1.5	33
98	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. <i>American Journal of Medicine</i> , 2018, 131, 555-564.e3.	1.5	38
99	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. <i>Translational Research</i> , 2018, 195, 25-47.	5.0	43
100	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1503-1519.	3.0	11
101	Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States. <i>Clinical Transplantation</i> , 2018, 32, e13425.	1.6	2
102	Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 873-884.	1.9	70
103	Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. <i>ESC Heart Failure</i> , 2018, 5, 592-602.	3.1	45
104	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e349-e351.	1.5	1
105	Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients. <i>BMC Nephrology</i> , 2018, 19, 107.	1.8	31
106	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	1.8	20
107	Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. <i>Clinical Nephrology</i> , 2018, 89, 314-329.	0.7	12
108	Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. <i>Transplantation</i> , 2017, 101, 157-165.	1.0	14



#	ARTICLE	IF	CITATIONS
109	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients. <i>Transplantation</i> , 2017, 101, 166-181.	1.0	37
110	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	6.1	365
111	Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications. <i>Kidney International</i> , 2017, 91, 529-531.	5.2	16
112	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 434-446.	2.0	28
113	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , 2017, 33, 1891-1900.	1.9	21
114	Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (<sc>MAGMA</sc>) Trial. <i>Clinical Cardiology</i> , 2017, 40, 633-640.	1.8	8
115	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 337-346.	1.9	52
116	TREATMENT WITH PATIROMER DECREASES ALDOSTERONE IN PATIENTS WITH HEART FAILURE, CHRONIC KIDNEY DISEASE, AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 912.	2.8	0
117	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2017, 46, 364-370.	3.1	7
118	The Author Replies. <i>Kidney International</i> , 2017, 92, 1016-1017.	5.2	0
119	Inhibition of the Renin–Angiotensin System: How Far Have We Come?. , 2017, , 77-95.		0
120	Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study. <i>American Journal of Nephrology</i> , 2017, 46, 323-332.	3.1	36
121	The Association of Sleep Duration and Quality with CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3708-3715.	6.1	59
122	Serum Creatinine in Female Patients with Cirrhosis Unfairly Bias Liver Transplant Wait List Ranking: Implications for Elimination of Gender Disparities in Access to Orthotopic Liver Transplantation. <i>Gastroenterology</i> , 2017, 152, S1120.	1.3	1
123	Robust Metabolomic Signature is Associated with Altered Renal Hemodynamics in Patients with Cirrhosis. <i>Gastroenterology</i> , 2017, 152, S1044.	1.3	1
124	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 762-769.	1.9	22
125	Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1409-1417.	4.5	18
126	Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. <i>Journal of Hypertension</i> , 2017, 35, S57-S63.	0.5	21



#	ARTICLE	IF	CITATIONS
127	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 10, 233-242.	1.8	5
128	Focus on Hyperkalemia Management: Expert Consensus and Economic Impacts. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S2-S20.	0.9	9
129	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 11, 1-7.	1.8	5
130	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S10-S19.	0.9	19
131	The Tyranny of Generic Immunosuppressants. <i>American Journal of Nephrology</i> , 2016, 44, 204-205.	3.1	1
132	Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study. <i>Transplantation Direct</i> , 2016, 2, e98.	1.6	0
133	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. <i>Kidney International</i> , 2016, 90, 861-868.	5.2	20
134	Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. <i>Transplantation</i> , 2016, 100, 407-415.	1.0	20
135	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocrine Practice</i> , 2016, 22, 753-762.	2.1	242
136	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F352-F361.	2.7	15
137	OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of Hypertension</i> , 2016, 34, e228-e229.	0.5	0
138	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1162-1166.	2.3	28
139	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 184-193.	1.0	110
140	Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. <i>Kidney International Reports</i> , 2016, 1, 256-268.	0.8	69
141	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. <i>American Journal of Kidney Diseases</i> , 2016, 68, 892-900.	1.9	70
142	Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting. <i>Hypertension</i> , 2016, 68, 1098-1099.	2.7	0
143	Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. <i>European Journal of Heart Failure</i> , 2016, 18, 216-216.	7.1	1
144	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016, 18, 299-307.	2.0	26

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. <i>American Journal of Nephrology</i> , 2016, 43, 229-236.	3.1	117
146	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1769-1776.	4.5	44
147	OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , 2016, 34, e229.	0.5	0
148	Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal of Nephrology</i> , 2016, 44, 169-169.	3.1	0
149	Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. <i>Kidney International</i> , 2016, 90, 696-704.	5.2	55
150	Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. <i>Digestive Diseases and Sciences</i> , 2016, 61, 309-316.	2.3	17
151	Current and future treatment options for managing hyperkalemia. <i>Kidney International Supplements</i> , 2016, 6, 29-34.	14.2	11
152	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016, 40, 247-257.	0.8	18
153	Noteworthy observations in hypertension from 2015. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 1-2.	2.0	1
154	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. <i>Postgraduate Medicine</i> , 2016, 128, 290-298.	2.0	24
155	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 642-652.	4.5	157
156	Human $\text{GRK4}^{142V}$ Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition. <i>Hypertension</i> , 2016, 67, 325-334.	2.7	28
157	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease. <i>Hypertension</i> , 2016, 67, 387-396.	2.7	134
158	Urinary Sodium and Potassium Excretion and CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1202-1212.	6.1	174
159	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 624-632.e2.	4.4	24
160	Patiromer Reduces Serum K <sup>+</sup> in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN. <i>Journal of Cardiac Failure</i> , 2015, 21, S107-S108.	1.7	4
161	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>European Journal of Heart Failure</i> , 2015, 17, 1057-1065.	7.1	134
162	Safety Events in Kidney Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1003-1008.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Is There an Optimal Strategy for Pretransplant Cardiovascular Screening?. <i>Transplantation</i> , 2015, 99, 656-657.	1.0	3
164	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	3.9	128
165	Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015, 17, 514-527.	2.0	18
166	Access to Kidney Transplantation: Is There a Potential Conflict of Interest?. <i>American Journal of Nephrology</i> , 2015, 41, 502-503.	3.1	0
167	Novel RAAS agonists and antagonists: clinical applications and controversies. <i>Nature Reviews Endocrinology</i> , 2015, 11, 242-252.	9.6	126
168	Assessment and Management of Hypertension in Transplant Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1248-1260.	6.1	138
169	CCR2 inhibition: a panacea for diabetic kidney disease?. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 666-667.	11.4	6
170	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 151.	7.4	370
171	New Agents for Hyperkalemia. <i>New England Journal of Medicine</i> , 2015, 372, 1569-1572.	27.0	6
172	Clinical perspectives on the rationale for potassium supplementation. <i>Postgraduate Medicine</i> , 2015, 127, 539-548.	2.0	26
173	A Prospective Controlled Study of Living Kidney Donors: Three-Year Follow-up. <i>American Journal of Kidney Diseases</i> , 2015, 66, 114-124.	1.9	142
174	Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte Pugh Class C Cirrhosis and Renal Dysfunction. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3491-3494.	2.3	1
175	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015, 88, 1427-1433.	5.2	90
176	Nonsteroidal MRA added to RAS blockade reduces albuminuria. <i>Nature Reviews Nephrology</i> , 2015, 11, 691-692.	9.6	2
177	The Authors Reply:. <i>Kidney International</i> , 2015, 87, 863-864.	5.2	0
178	The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. <i>Current Cardiology Reports</i> , 2015, 17, 95.	2.9	9
179	Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015, 44, 550.	1.6	2
180	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , 2015, 87, 527-534.	5.2	70

#	ARTICLE	IF	CITATIONS
181	Patiomer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. <i>New England Journal of Medicine</i> , 2015, 372, 211-221.	27.0	521
182	Hematologic Complications of Chronic Kidney Disease. , 2015, , 277-284.		0
183	Urine Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 267-274.	1.9	58
184	The Use of Thiazides in Chronic Kidney Disease. <i>Current Hypertension Reviews</i> , 2015, 10, 81-85.	0.9	3
185	Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Hypertension</i> , 2014, 16, 875-882.	2.0	95
186	Usability of Mobile Technology to Screen for Drug-Drug Interactions in Kidney Transplant Patients. <i>American Journal of Nephrology</i> , 2014, 40, 97-104.	3.1	7
187	Hypertension and kidney disease. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 855-857.	2.3	5
188	Treatment-Resistant Hypertension in the Transplant Recipient. <i>Seminars in Nephrology</i> , 2014, 34, 560-570.	1.6	13
189	Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. <i>Hepatology</i> , 2014, 59, 1532-1542.	7.3	108
190	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1554-1562.	6.1	60
191	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Current Medical Research and Opinion</i> , 2014, 30, 1759-1768.	1.9	94
192	Vascular stiffness as a surrogate measure of mortality in patients with chronic kidney disease. <i>Journal of Hypertension</i> , 2014, 32, 744-745.	0.5	4
193	Refractory Hypertension. <i>Hypertension</i> , 2014, 63, 447-448.	2.7	3
194	Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 306-313.	2.0	39
195	Specific Management of Anemia and Hypertension in Renal Transplant Recipients: Influence of Renin-Angiotensin System Blockade. <i>American Journal of Nephrology</i> , 2014, 39, 1-7.	3.1	15
196	Assessment and Management of Hypertension in Patients on Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1630-1646.	6.1	134
197	A Pilot Study to Evaluate Renal Hemodynamics in Cirrhosis by Simultaneous Glomerular Filtration Rate, Renal Plasma Flow, Renal Resistive Indices and Biomarkers Measurements. <i>American Journal of Nephrology</i> , 2014, 39, 543-552.	3.1	30
198	Effect of Canagliflozin (CANA) in Patients With Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR). <i>Canadian Journal of Diabetes</i> , 2014, 38, S12.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Salt, hypertension, and proteinuria in diabetic nephropathy. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 351-352.	11.4	5
200	Hypertension. <i>Annals of Internal Medicine</i> , 2014, 161, ITC1.	3.9	24
201	Pharmacogenomics of G Protein-Coupled Receptor Signaling and Other Pathways in Essential Hypertension. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 299-312.	0.2	1
202	A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. <i>American Journal of Kidney Diseases</i> , 2013, 62, 577-586.	1.9	323
203	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. <i>American Journal of Medicine</i> , 2013, 126, 501-508.	1.5	56
204	Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 236-243.	2.3	16
205	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013, 381, 537-545.	13.7	132
206	Lower Blood Pressure (BP) with Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM). <i>Canadian Journal of Diabetes</i> , 2013, 37, S3.	0.8	2
207	Obesity, blood pressure, and cardiovascular outcomes – Authors' reply. <i>Lancet, The</i> , 2013, 381, 1982-1983.	13.7	0
208	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 201-213.	1.9	174
209	Efficacy of Amlodipine/Olmesartan Medoxomil ± Hydrochlorothiazide in Patients Aged ≥ 65 or < 65 Years With Uncontrolled Hypertension on Prior Monotherapy. <i>Postgraduate Medicine</i> , 2013, 125, 124-134.	2.0	7
210	Angiotensin II Blockade after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 167-168.	6.1	1
211	Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis. <i>American Journal of Nephrology</i> , 2013, 38, 345-354.	3.1	27
212	Antibody-Mediated Allograft Rejection. <i>Transplantation</i> , 2013, 95, 128-136.	1.0	48
213	Blood pressure response with fixed-dose combination therapy. <i>Journal of Hypertension</i> , 2013, 31, 1692-1701.	0.5	6
214	Benefits Improvement and Protection Act's Impact on Transplantation Rates Among Elderly MEDICARE Beneficiaries With End-Stage Renal Disease. <i>Transplantation</i> , 2013, 95, 463-469.	1.0	0
215	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Circulation</i> , 2012, 126, 617-663.	1.6	255
216	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	5.2	31

#	ARTICLE	IF	CITATIONS
217	Genotype-based changes in serum uric acid affect blood pressure. <i>Kidney International</i> , 2012, 81, 502-507.	5.2	75
218	Improving the Estimating Equation for GFR – A Clinical Perspective. <i>New England Journal of Medicine</i> , 2012, 367, 75-76.	27.0	4
219	The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. <i>Postgraduate Medicine</i> , 2012, 124, 40-52.	2.0	11
220	Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insufficiency Cohort Study. <i>American Journal of Nephrology</i> , 2012, 36, 397-404.	3.1	12
221	A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting: Figure 1. <i>BMJ Open</i> , 2012, 2, e000902.	1.9	17
222	Anemia After Kidney Transplantation; Its Prevalence, Risk Factors, and Independent Association With Graft and Patient Survival. <i>Transplantation</i> , 2012, 93, 923-928.	1.0	47
223	A 72-Year-Old Woman With Several Months of Weight Loss and Generalized Weakness. <i>American Journal of the Medical Sciences</i> , 2012, 344, 142-145.	1.1	0
224	Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2012, 60, 250-261.	1.9	207
225	Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. <i>Cardiovascular Therapeutics</i> , 2012, 30, 342-350.	2.5	25
226	Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? con position. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 443-447.	2.3	6
227	Plant Protein Intake is Associated With Fibroblast Growth Factor 23 and Serum Bicarbonate Levels in Patients With Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort Study. , 2012, 22, 379-388.e1.		88
228	Thiazide and Thiazide-Like Diuretics. <i>Hypertension</i> , 2012, 59, 1089-1090.	2.7	0
229	Role of dietary therapies in the prevention and treatment of hypertension. <i>Nature Reviews Nephrology</i> , 2012, 8, 413-422.	9.6	9
230	Thiazide and Thiazide-like Diuretics: An Opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease. <i>Current Hypertension Reports</i> , 2012, 14, 416-420.	3.5	18
231	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Journal of the American College of Cardiology</i> , 2012, 60, 434-480.	2.8	328
232	Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 36, 19-26.	3.1	18
233	Eosinophilia as an early indicator of pancreatic allograft rejection. <i>Clinical Transplantation</i> , 2012, 26, 238-241.	1.6	12
234	Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the <sc>FAVORIT</sc> study. <i>Clinical Transplantation</i> , 2012, 26, E438-46.	1.6	46

#	ARTICLE	IF	CITATIONS
235	Antihypertensive Drugs. , 2012, , 1824-1878.		1
236	Dual Blockade of the Renin-“Angiotensin”-Aldosterone System: Benefits Versus Adverse Outcomes. , 2012, , 453-465.		0
237	Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. <i>Kidney International</i> , 2011, 80, 288-294.	5.2	57
238	Acute fall in glomerular filtration rate with renin-“angiotensin system inhibition: a biomeasure of therapeutic success?. <i>Kidney International</i> , 2011, 80, 235-237.	5.2	15
239	Management of hypertension in the transplant patient. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 425-432.	2.3	15
240	Readmissions After Unauthorized Discharges in the Cardiovascular Setting. <i>Medical Care</i> , 2011, 49, 215-224.	2.4	11
241	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-“angiotensin”-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. <i>Journal of Hypertension</i> , 2011, 29, 2031-2037.	0.5	2
242	A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide. <i>Journal of Clinical Hypertension</i> , 2011, 13, 404-412.	2.0	73
243	Angiotensin-Converting Enzyme Inhibitors. <i>Journal of Clinical Hypertension</i> , 2011, 13, 667-675.	2.0	83
244	Determinants of Blood Pressure Response to Low-Salt Intake in a Healthy Adult Population. <i>Journal of Clinical Hypertension</i> , 2011, 13, 795-800.	2.0	21
245	52 Prevalence of CVD Risk Factors and their Treatment in Chronic, Stable Kidney Transplant Recipients in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. <i>American Journal of Kidney Diseases</i> , 2011, 57, B29.	1.9	0
246	Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients. <i>Circulation</i> , 2011, 123, 1763-1770.	1.6	171
247	A Randomized, Double-Blind, Forced-Titration Study to Compare Olmesartan Medoxomil versus Losartan Potassium in Patients with Stage 1 and 2 Hypertension. <i>Postgraduate Medicine</i> , 2011, 123, 80-87.	2.0	16
248	The Role of Angiotensin Receptor Blockers in Diabetic Nephropathy. <i>Postgraduate Medicine</i> , 2011, 123, 109-121.	2.0	11
249	Body Mass Index-Mortality Paradox in Hemodialysis Patients. <i>Hypertension</i> , 2011, 58, 989-990.	2.7	7
250	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. <i>Hypertension</i> , 2011, 57, 174-179.	2.7	55
251	Efficacy and Safety of Carvedilol in Treatment of Heart Failure with Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2011, 4, 18-26.	3.9	70
252	Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. <i>Kidney International</i> , 2011, 79, 897-907.	5.2	164



#	ARTICLE	IF	CITATIONS
253	The Evolving Role of mTOR Inhibition in Transplantation Tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 408-415.	6.1	60
254	Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2612-2619.	4.5	48
255	Acute Kidney Injury following Cardiac Surgery: Role of Perioperative Blood Pressure Control. <i>American Journal of Nephrology</i> , 2011, 33, 438-452.	3.1	39
256	Optimal Treatment Strategies for Patients With Hypertension and Diabetes. <i>Hypertension</i> , 2011, 58, 758-759.	2.7	1
257	Response to Letter Regarding Article, "Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension". <i>Circulation</i> , 2011, 123, .	1.6	0
258	The Author Replies:. <i>Kidney International</i> , 2011, 79, 1379-1380.	5.2	0
259	Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. <i>Kidney International</i> , 2011, 80, 1016-1017.	5.2	6
260	Measured GFR Does Not Outperform Estimated GFR in Predicting CKD-related Complications. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1931-1937.	6.1	58
261	Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2403-2410.	4.5	37
262	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011, 24, 263-273.	2.0	12
263	Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies. , 2011, , 165-183.		0
264	Recognizing the link between chronic kidney disease and cardiovascular disease. <i>American Journal of Managed Care</i> , 2011, 17 Suppl 15, S396-402.	1.1	9
265	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , 2010, 28, 186-193.	0.5	16
266	The Independent Association Between Serum Uric Acid and Graft Outcomes After Kidney Transplantation. <i>Transplantation</i> , 2010, 89, 573-579.	1.0	56
267	A Study of Renal Outcomes in Obese Living Kidney Donors. <i>Transplantation</i> , 2010, 90, 993-999.	1.0	60
268	Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 437-443.	2.0	4
269	Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?. <i>Current Hypertension Reports</i> , 2010, 12, 369-377.	3.5	21
270	Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study. <i>Current Hypertension Reports</i> , 2010, 12, 313-315.	3.5	4

#	ARTICLE	IF	CITATIONS
271	Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2010, 55, 441-451.	1.9	320
272	Cigarette Smoking, Kidney Function, and Mortality After Live Donor Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 55, 907-915.	1.9	42
273	Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1429-1434.	3.4	9
274	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , 2010, 23, 447-460.	1.6	28
275	Dry-Weight. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1255-1260.	4.5	137
276	Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary Study. <i>American Journal of Hypertension</i> , 2010, 23, 282-289.	2.0	192
277	Acute Kidney Injury and Cardiovascular Outcomes in Acute Severe Hypertension. <i>Circulation</i> , 2010, 121, 2183-2191.	1.6	55
278	Reasons for discharges against medical advice: a qualitative study. <i>BMJ Quality and Safety</i> , 2010, 19, 420-424.	3.7	34
279	Relative Plasma Volume Monitoring and Blood Pressure Control. <i>Hypertension</i> , 2010, 55, 226-227.	2.7	4
280	Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 356-363.	2.0	23
281	Hypervolemia and Blood Pressure. <i>Hypertension</i> , 2010, 56, 341-343.	2.7	12
282	Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 531-548.	4.5	196
283	Dietary Fructose and Elevated Levels of Blood Pressure. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1416-1418.	6.1	2
284	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 449-457.	0.7	111
285	The Death of John Paul Jones and Resurrection as "Father of the US Navy". <i>American Journal of Nephrology</i> , 2010, 31, 90-94.	3.1	1
286	Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. <i>American Journal of Nephrology</i> , 2010, 31, 469-470.	3.1	24
287	Variability of Creatinine Measurements in Clinical Laboratories: Results from the CRIC Study. <i>American Journal of Nephrology</i> , 2010, 31, 426-434.	3.1	97
288	Endothelin-receptor antagonists for treating hypertension. <i>Nature Reviews Nephrology</i> , 2010, 6, 192-194.	9.6	1

#	ARTICLE	IF	CITATIONS
289	Have we fallen off target with concerns surrounding dual RAAS blockade?. <i>Kidney International</i> , 2010, 78, 539-545.	5.2	15
290	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	2.8	215
291	Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: The Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>Journal of Clinical Lipidology</i> , 2010, 4, 165-172.	1.5	7
292	Achieving lipid targets in adults with type 2 diabetes: The Stop Atherosclerosis in Native Diabetics Study. <i>Journal of Clinical Lipidology</i> , 2010, 4, 435-443.	1.5	9
293	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. <i>Lancet</i> , 2010, 375, 1173-1181.	13.7	472
294	Hypertension and the Kidney. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 2045-2050.	4.5	21
295	β-Blockers in the Treatment of Hypertension: Are There Clinically Relevant Differences?. <i>Postgraduate Medicine</i> , 2009, 121, 90-98.	2.0	27
296	The Renoprotective Effects of RAS Inhibition: Focus on Prevention and Treatment of Chronic Kidney Disease. <i>Postgraduate Medicine</i> , 2009, 121, 96-103.	2.0	13
297	The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2009, 169, 1156.	3.8	501
298	Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. <i>European Journal of Heart Failure</i> , 2009, 11, 542-550.	7.1	17
299	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. <i>Postgraduate Medicine</i> , 2009, 121, 164-165.	2.0	0
300	Optimal Dietary Strategies for Reducing Incident Hypertension. <i>Hypertension</i> , 2009, 54, 698-699.	2.7	3
301	Assessing the Blood Pressure Lowering Efficacy of Antihypertensive Medications: Which Blood Pressures Should We Use?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 155-158.	2.0	1
302	Safety and Feasibility of Achieving Lower Systolic Blood Pressure Goals in Persons With Type 2 Diabetes: The SANDS Trial. <i>Journal of Clinical Hypertension</i> , 2009, 11, 540-548.	2.0	18
303	What Is Left Ventricular Hypertrophy and Is There a Reason to Regress Left Ventricular Hypertrophy?. <i>Journal of Clinical Hypertension</i> , 2009, 11, 407-410.	2.0	3
304	The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. <i>Clinical Transplantation</i> , 2009, 23, 930-937.	1.6	37
305	Prescribing Trends and Drug Budget Impact of the ARBs in the UK. <i>Value in Health</i> , 2009, 12, 302-308.	0.3	10
306	Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 277-285.	2.3	2

#	ARTICLE	IF	CITATIONS
307	Renin Angiotensin System Inhibition in the Older Person: A Review. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 245-257.	2.6	9
308	Drug interactions in transplant patients: what everyone should know. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 404-411.	2.0	55
309	A Study of Renal Outcomes in African American Living Kidney Donors. <i>Transplantation</i> , 2009, 88, 1371-1376.	1.0	46
310	Predictors of Compliance with Antihypertensive Therapy in a High-Risk Medicaid Population. <i>Journal of the National Medical Association</i> , 2009, 101, 34-39.	0.8	66
311	Minimizing the Risk of Chronic Allograft Nephropathy. <i>Transplantation</i> , 2009, 87, S14-S18.	1.0	18
312	Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. <i>Journal of Hypertension</i> , 2009, 27, 886-893.	0.5	41
313	Are we "ONTARGET" yet with regard to optimal antihypertensive regimens?. <i>Current Hypertension Reports</i> , 2008, 10, 385-386.	3.5	0
314	Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. <i>Arthritis and Rheumatism</i> , 2008, 58, 2874-2881.	6.7	86
315	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. <i>Kidney International</i> , 2008, 74, 364-369.	5.2	135
316	MYH9 is associated with nondiabetic end-stage renal disease in African Americans. <i>Nature Genetics</i> , 2008, 40, 1185-1192.	21.4	587
317	A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. <i>Transplant International</i> , 2008, 21, 908-914.	1.6	8
318	Newer Combination Therapies in the Management of Hypertension: An Update. <i>Journal of Clinical Hypertension</i> , 2008, 10, 398-405.	2.0	3
319	Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. <i>Journal of Clinical Hypertension</i> , 2008, 10, 146-152.	2.0	21
320	Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2198-2205.	2.8	240
321	The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. <i>American Heart Journal</i> , 2008, 155, 823-828.	2.7	109
322	Risk-Based Classification of Hypertension and the Role of Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2008, 10, 4-12.	2.0	22
323	Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: A post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. <i>Clinical Therapeutics</i> , 2008, 30, 2354-2365.	2.5	10
324	Is Activated Vitamin D Supplementation Renoprotective?. <i>Hypertension</i> , 2008, 52, 211-212.	2.7	6

#	ARTICLE	IF	CITATIONS
325	Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 919-925.	0.7	49
326	Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1678.	7.4	217
327	Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. <i>Postgraduate Medicine</i> , 2008, 120, 33-42.	2.0	15
328	Renal Function and Cardiovascular Response to Mental Stress. <i>American Journal of Nephrology</i> , 2008, 28, 304-310.	3.1	5
329	Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. <i>Journal of Hypertension</i> , 2008, 26, 729-736.	0.5	20
330	The balance of angiotensin II and nitric oxide in kidney diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 51-56.	2.0	15
331	Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?. <i>Current Opinion in Organ Transplantation</i> , 2008, 13, 614-621.	1.6	22
332	Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. <i>Transactions of the American Clinical and Climatological Association</i> , 2008, 119, 53-61; discussion 61-3.	0.5	0
333	Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 5??15.	2.2	8
334	Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1540-1546.	6.1	280
335	Microalbuminuria and Cardiovascular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 581-590.	4.5	277
336	Usefulness of ARBs and ACE Inhibitors in the Prevention of Vascular Dementia in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 175-182.	0.6	21
337	Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. <i>Future Cardiology</i> , 2007, 3, 519-524.	1.2	18
338	COX-2 Inhibitors And Cardiovascular Risk. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 159-174.	2.4	9
339	How Do You Define "Hypertension" in a Patient With Type 1 Diabetes?. <i>Hypertension</i> , 2007, 49, 13-14.	2.7	2
340	The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 766-785.	4.5	30
341	Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?. <i>Current Opinion in Nephrology and Hypertension</i> , 2007, 16, 416-421.	2.0	9
342	Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 103-112.	2.0	22

#	ARTICLE	IF	CITATIONS
343	The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk. <i>Journal of Clinical Hypertension</i> , 2007, 9, 23-30.	2.0	16
344	Time to Achieve Blood-Pressure Goal: Influence of Dose of Valsartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. <i>American Journal of Hypertension</i> , 2007, 20, 807-815.	2.0	46
345	Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?. <i>Clinical Therapeutics</i> , 2007, 29, 1803-1824.	2.5	152
346	Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. <i>Journal of the American Society of Hypertension</i> , 2007, 1, 264-277.	2.3	86
347	Cigarette Smoking and Incident Chronic Kidney Disease: A Systematic Review. <i>American Journal of Nephrology</i> , 2007, 27, 342-351.	3.1	53
348	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	1.5	65
349	Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. <i>Clinical Transplantation</i> , 2007, 21, 491-497.	1.6	20
350	Exercise-Induced Hypertension, Endothelial Dysfunction, and Coronary Artery Disease in a Marathon Runner. <i>American Journal of Cardiology</i> , 2007, 99, 743-744.	1.6	27
351	Direct renin inhibitors: Where will they fit in for antihypertensive treatment?. <i>Current Hypertension Reports</i> , 2007, 9, 389-391.	3.5	0
352	Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes—the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>American Heart Journal</i> , 2006, 152, 867-875.	2.7	26
353	Providing End-Organ Protection With Renin-Angiotensin System Inhibition: The Evidence So Far. <i>Journal of Clinical Hypertension</i> , 2006, 8, 99-107.	2.0	18
354	Cyclosporine reduction causes decreasing of angiotensin II and transforming growth factor-beta expression in chronic allograft nephropathy. <i>Journal of Cardiothoracic-Renal Research</i> , 2006, 1, 81-88.	0.1	1
355	The metabolic syndrome: a call to action. <i>Coronary Artery Disease</i> , 2006, 17, 77-80.	0.7	39
356	Clinical trials report. <i>Current Hypertension Reports</i> , 2006, 8, 393-394.	3.5	1
357	An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2006, 26, 268-275.	3.1	105
358	Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects. <i>Archives of Internal Medicine</i> , 2005, 165, 181.	3.8	62
359	The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: are we there yet?. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 39-41.	2.0	1
360	Salt intake and progression of chronic kidney disease: An overlooked modifiable exposure? A commentary. <i>American Journal of Kidney Diseases</i> , 2005, 45, 176-188.	1.9	79

#	ARTICLE	IF	CITATIONS
361	Current status of kidney and pancreas transplantation in the United States, 1994â€“2003. American Journal of Transplantation, 2005, 5, 904-915.	4.7	143
362	Does dietary salt increase the risk for progression of kidney disease?. Current Hypertension Reports, 2005, 7, 385-391.	3.5	21
363	Reduction in Microalbuminuria. Hypertension, 2005, 45, 181-182.	2.7	7
364	A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives. Hypertension, 2005, 46, 508-513.	2.7	35
365	Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics?. Nephrology Dialysis Transplantation, 2005, 20, 2022-2024.	0.7	2
366	The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. American Journal of Hypertension, 2005, 18, 100-105.	2.0	22
367	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. Journal of the American College of Cardiology, 2005, 45, 1051-1060.	2.8	225
368	Renal Protection in Chronic Kidney Disease. , 2005, , 281-294.		2
369	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. , 2005, , 543-556.		0
370	Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. American Journal of Nephrology, 2004, 24, 379-386.	3.1	57
371	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney International, 2004, 65, 1991-2002.	5.2	189
372	Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asiaâ€“Pacific Rim. Kidney International, 2004, 66, S38-S39.	5.2	28
373	Clinical trials report. Current Hypertension Reports, 2004, 6, 365-368.	3.5	3
374	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Current Hypertension Reports, 2004, 6, 98-105.	3.5	22
375	Blood pressure management in the kidney transplant recipient. Advances in Chronic Kidney Disease, 2004, 11, 172-183.	1.4	23
376	Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. Advances in Chronic Kidney Disease, 2004, 11, 24-40.	2.1	11
377	Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: the aadvance trial. American Journal of Hypertension, 2004, 17, S112-S113.	2.0	1
378	Advances in the management of hypertension and diabetes: Why we need to integrate biology, evidence, and treatment strategies. American Journal of Hypertension, 2004, 17, S1-S1.	2.0	0



#	ARTICLE	IF	CITATIONS
379	Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor. <i>Journal of Clinical Hypertension</i> , 2004, 6, 134-143.	2.0	57
380	Healthy Diet and Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2004, 6, 381-382.	2.0	0
381	Dietary Salt, Blood Pressure, and Microalbuminuria. <i>Journal of Clinical Hypertension</i> , 2004, 6, 23-26.	2.0	10
382	Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. <i>Journal of Clinical Hypertension</i> , 2004, 6, 315-325.	2.0	5
383	Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. <i>Transplantation</i> , 2004, 77, 422-425.	1.0	31
384	Retransplantation in patients with graft loss caused by polyoma virus nephropathy. <i>Transplantation</i> , 2004, 77, 131-133.	1.0	81
385	BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression. <i>Transplantation</i> , 2004, 78, 1069-1073.	1.0	61
386	Are the oxygen costs of kidney function highly regulated?. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 67-71.	2.0	29
387	Chronic kidney disease: Blood pressure, treatment goals, and cardiovascular outcomes. <i>Current Hypertension Reports</i> , 2003, 5, 405-407.	3.5	2
388	RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. <i>Current Hypertension Reports</i> , 2003, 5, 408-417.	3.5	63
389	Histological Grading of Chronic Pancreas Allograft Rejection/Graft Sclerosis. <i>American Journal of Transplantation</i> , 2003, 3, 599-605.	4.7	40
390	Preemptive Renal Transplantation: Why Not?. <i>American Journal of Transplantation</i> , 2003, 3, 1336-1340.	4.7	54
391	Coxibsâ€™Beyond the GI Tract. <i>Journal of Pain and Symptom Management</i> , 2003, 25, 41-49.	1.2	37
392	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <i>American Heart Journal</i> , 2003, 146, 591-604.	2.7	122
393	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. <i>Journal of Clinical Hypertension</i> , 2003, 5, 202-209.	2.0	82
394	Treatment of Hypertension in the Very Elderly: a Clinician's Point of View. <i>Journal of Clinical Hypertension</i> , 2003, 5, 330-335.	2.0	64
395	Optimizing target-organ protection in patients with diabetes mellitus: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers?. <i>Current Hypertension Reports</i> , 2003, 5, 192-198.	3.5	1
396	Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. <i>Transplantation Reviews</i> , 2003, 17, 20-30.	2.9	3

#	ARTICLE	IF	CITATIONS
397	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy<sub>title>>Results From the RENAAL Study</sub>. Archives of Internal Medicine, 2003, 163, 1555.	3.8	399
398	Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. Current Opinion in Nephrology and Hypertension, 2003, 12, 57-60.	2.0	11
399	Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. Transplantation, 2003, 75, 1186-1190.	1.0	40
400	Antihypertensive therapy: Progression of Renal Injury. , 2003, , 209-240.		0
401	Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 2145-2151.	6.1	398
402	Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation, 2002, 73, 1350-1353.	1.0	62
403	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. Journal of Clinical Hypertension, 2002, 4, 420-440.	2.0	30
404	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. American Journal of Hypertension, 2002, 15, 550-556.	2.0	46
405	Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. American Journal of Kidney Diseases, 2002, 39, 753-761.	1.9	10
406	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: A pilot case-control study. American Journal of Kidney Diseases, 2002, 39, 1096-1101.	1.9	38
407	Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current Hypertension Reports, 2002, 4, 333-335.	3.5	2
408	Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney International, 2002, 62, 1482-1492.	5.2	12
409	Pancreas allograft biopsy: safety of percutaneous biopsy???results of a large experience. Transplantation, 2002, 73, 553-555.	1.0	81
410	Current perspective on the cardiovascular effects of coxibs.. Cleveland Clinic Journal of Medicine, 2002, 69, S147-S147.	1.3	13
411	Renal effects of nonselective NSAIDs and coxibs.. Cleveland Clinic Journal of Medicine, 2002, 69, S153-S153.	1.3	74
412	The ? Blockers: Are They as Protective in Hypertension as in other Cardiovascular Conditions?. Journal of Clinical Hypertension, 2001, 3, 236-243.	2.0	8
413	Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib. Circulation, 2001, 104, 2280-2288.	1.6	353
414	Implications from the Heart Outcomes Prevention Evaluation Study. Current Opinion in Nephrology and Hypertension, 2001, 10, 61-63.	2.0	0

#	ARTICLE	IF	CITATIONS
415	Hypertension in Patients with Type 2 Diabetes. Hospital Practice (1995), 2001, 36, 41-54.	1.0	0
416	Appropriate Use of Calcium Antagonists in Hypertension. Hospital Practice (1995), 2001, 36, 47-55.	1.0	0
417	The Inevitability of Renal Function Loss in Patients with Hypercreatinemia. American Journal of Nephrology, 2001, 21, 386-389.	3.1	3
418	Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney International, 2001, 59, 1567-1573.	5.2	166
419	Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S217-S222.	1.7	0
420	The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S188-S190.	1.7	2
421	Morphological Spectrum of Polyoma Virus Disease in Renal Allografts: Diagnostic Accuracy of Urine Cytology. American Journal of Transplantation, 2001, 1, 373-381.	4.7	146
422	RECIPIENT OUTCOME AFTER RECEIVING A LAPROSCOPICALLY HARVESTED KIDNEY FROM A LIVING DONOR. Transplantation, 2001, 72, 355-356.	1.0	2
423	Implications of a Health Lifestyle and Medication Analysis for Improving Hypertension Control. Archives of Internal Medicine, 2000, 160, 481.	3.8	94
424	Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Current Opinion in Nephrology and Hypertension, 2000, 9, 403-411.	2.0	31
425	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. Journal of Clinical Pharmacology, 2000, 40, 815-825.	2.0	16
426	Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?. Current Hypertension Reports, 2000, 2, 497-499.	3.5	3
427	Angiotensin-Converting Enzyme Inhibitor-associated Elevations in Serum Creatinine. Archives of Internal Medicine, 2000, 160, 685-93.	3.8	679
428	Diuretics and $\beta$ -blockers: Is there a risk for dyslipidemia?. American Heart Journal, 2000, 139, 174-184.	2.7	50
429	Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism: Clinical and Experimental, 2000, 49, 1491-1495.	3.4	26
430	Achieving low blood pressure for the kidney: is there really a problem? Wednesday, may 17, broadway ballroom north, 3:00 pm to 5:00 pm. new blood pressure goals: reality or fantasy-the importance of combination therapy. American Journal of Hypertension, 2000, 13, S329.	2.0	0
431	Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. American Journal of Hypertension, 2000, 13, 1180-1188.	2.0	29
432	The Role of Multiple Drug Therapy for Controlling Hypertension in African Americans. Journal of Clinical Hypertension, 2000, 2, 99-108.	2.0	1

#	ARTICLE	IF	CITATIONS
433	The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial. <i>Journal of Clinical Hypertension</i> , 2000, 2, 181-186.	2.0	5
434	Hypertensive cardiovascular disease in African Americans. <i>Current Hypertension Reports</i> , 1999, 1, 521-528.	3.5	28
435	Hypertension: Goal systolic and diastolic blood pressure. <i>Current Hypertension Reports</i> , 1999, 1, 411-413.	3.5	0
436	From hypertension to heart disease: interfering with progression Diabetes and hypertension: blood pressure control benefits and consequences.. <i>American Journal of Hypertension</i> , 1999, 12, 222.	2.0	0
437	Risk for posttransplant diabetes mellitus with current immunosuppressive medications. <i>American Journal of Kidney Diseases</i> , 1999, 34, 1-13.	1.9	363
438	Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. <i>Human Pathology</i> , 1999, 30, 970-977.	2.0	243
439	Indicators and Treatment of Hypertensive Heart Disease. <i>Hospital Practice (1995)</i> , 1999, 34, 93-107.	1.0	0
440	A COMPARISON OF RECIPIENT RENAL OUTCOMES WITH LAPAROSCOPIC VERSUS OPEN LIVE DONOR NEPHRECTOMY. <i>Transplantation</i> , 1999, 67, 722-728.	1.0	214
441	REGULATION OF THE EPITHELIAL CELL-SPECIFIC INTEGRIN, CD103, BY HUMAN CD8+ CYTOLYTIC T LYMPHOCYTES1. <i>Transplantation</i> , 1999, 67, 1418-1425.	1.0	51
442	ISLET CELL DAMAGE ASSOCIATED WITH TACROLIMUS AND CYCLOSPORINE: MORPHOLOGICAL FEATURES IN PANCREAS ALLOGRAFT BIOPSIES AND CLINICAL CORRELATION1. <i>Transplantation</i> , 1999, 68, 396-402.	1.0	298
443	How Low Should We Treat Blood Pressure and Why?. <i>Journal of Clinical Hypertension</i> , 1999, 1, 199-208.	2.0	2
444	Efficacy of Low-Dose Combination of Bisoprolol/Hydrochlorothiazide Compared With Amlodipine and Enalapril in Men and Women With Essential Hypertension. <i>American Journal of Cardiology</i> , 1998, 81, 1363-1365.	1.6	8
445	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. <i>Kidney International</i> , 1998, 54, 1283-1289.	5.2	246
446	Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. <i>American Journal of Hypertension</i> , 1998, 11, 914-920.	2.0	42
447	The rationale for combination versus single-entity therapy in hypertension. <i>American Journal of Hypertension</i> , 1998, 11, 163S-169S.	2.0	25
448	Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives. <i>Hypertension</i> , 1998, 31, 1088-1096.	2.7	124
449	Impact of Salt Intake on Blood Pressure and Proteinuria in Diabetes: Importance of the Renin-Angiotensin System. <i>Mineral and Electrolyte Metabolism</i> , 1998, 24, 438-445.	1.1	14
450	MYCOPHENOLATE MOFETIL REDUCES THE RISK OF ACUTE REJECTION LESS IN AFRICAN-AMERICAN THAN IN CAUCASIAN KIDNEY RECIPIENTS1. <i>Transplantation</i> , 1998, 65, 242-248.	1.0	39

#	ARTICLE	IF	CITATIONS
451	HISTOLOGIC GRADING OF ACUTE ALLOGRAFT REJECTION IN PANCREAS NEEDLE BIOPSY. <i>Transplantation</i> , 1998, 66, 1741-1745.	1.0	68
452	Effect of Dietary Sodium on Insulin Sensitivity in Older, Obese, Sedentary Hypertensives. <i>American Journal of Hypertension</i> , 1997, 10, 964-970.	2.0	8
453	Increased living donor volunteer rates with a formal recipient family education program. <i>American Journal of Kidney Diseases</i> , 1997, 29, 739-745.	1.9	77
454	The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. <i>American Journal of Kidney Diseases</i> , 1997, 29, 800-803.	1.9	1
455	Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , 1997, 20, 562-568.	1.8	14
456	SAFE PANCREAS TRANSPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE <sup>1</sup> . <i>Transplantation</i> , 1997, 63, 1294-1299.	1.0	28
457	EVALUATION OF PANCREAS TRANSPLANT NEEDLE BIOPSY. <i>Transplantation</i> , 1997, 63, 1579-1586.	1.0	115
458	A NOVEL APPROACH TO THE TREATMENT OF CHRONIC ALLOGRAFT NEPHROPATHY <sup>1</sup> . <i>Transplantation</i> , 1997, 64, 1706-1710.	1.0	140
459	Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients. <i>Hypertension</i> , 1997, 30, 140-145.	2.7	133
460	Salt and Blood Pressure Responses to Calcium Antagonism in Hypertensive Patients. <i>Hypertension</i> , 1997, 30, 422-427.	2.7	36
461	Hypertension in Elderly African-Americans. <i>The American Journal of Geriatric Cardiology</i> , 1997, 6, 13-20.	0.6	0
462	Gender considerations in hypertension pathophysiology and treatment. <i>American Journal of Medicine</i> , 1996, 101, 10S-21S.	1.5	38
463	Therapeutic challenges in the obese diabetic patient with hypertension. <i>American Journal of Medicine</i> , 1996, 101, 33S-46S.	1.5	43
464	Double adult renal allografts: A technique for expansion of the cadaveric kidney donor pool. <i>Surgery</i> , 1996, 120, 580-584.	1.9	89
465	Pancreas Transplantation for Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 1996, 27, 444-450.	1.9	42
466	Significance of the banff borderline biopsy. <i>American Journal of Kidney Diseases</i> , 1996, 28, 585-588.	1.9	77
467	Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. <i>Clinical Therapeutics</i> , 1996, 18, 411-428.	2.5	51
468	Equivalent Success of Simultaneous Pancreas Kidney and Solitary Pancreas Transplantation. <i>Annals of Surgery</i> , 1996, 224, 440-452.	4.2	117

#	ARTICLE	IF	CITATIONS
469	ISOLATED PANCREAS REJECTION IN COMBINED KIDNEY PANCREAS TRANSPLANTATION. <i>Transplantation</i> , 1996, 61, 974-977.	1.0	73
470	LATE PANCREAS ALLOGRAFT REJECTION. <i>Transplantation</i> , 1996, 62, 539-543.	1.0	8
471	DOUBLE RENAL ALLOGRAFTS SUCCESSFULLY INCREASE UTILIZATION OF KIDNEYS FROM OLDER DONORS WITHIN A SINGLE ORGAN PROCUREMENT ORGANIZATION. <i>Transplantation</i> , 1996, 62, 1581-1583.	1.0	92
472	HISTOLOGIC FINDINGS IN ISLETS OF WHOLE PANCREAS ALLOGRAFTS. <i>Transplantation</i> , 1996, 62, 1770-1772.	1.0	27
473	Insulin Resistance, Elevated Glomerular Filtration Fraction, and Renal Injury. <i>Hypertension</i> , 1996, 28, 127-132.	2.7	131
474	First-Line Therapy Option with Low-Dose Bisoprolol Fumarate and Low-Dose Hydrochlorothiazide in Patients with Stage I and Stage II Systemic Hypertension. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 182-188.	2.0	44
475	Hypertension in Diabetic Patients: An Update of Interventional Studies to Preserve Renal Function. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 73-80.	2.0	9
476	Diltiazem: Ten Years of Clinical Experience in the Treatment of Hypertension. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 220-232.	2.0	34
477	Salt intake and hypertensive renal injury in African-Americans a therapeutic perspective. <i>American Journal of Hypertension</i> , 1995, 8, 635-644.	2.0	20
478	Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. <i>American Heart Journal</i> , 1995, 130, 359-366.	2.7	79
479	Salt-Induced Increases in Systolic Blood Pressure Affect Renal Hemodynamics and Proteinuria. <i>Hypertension</i> , 1995, 25, 1339-1344.	2.7	93
480	Differing Mechanisms of Action of Angiotensin-Converting Enzyme Inhibition in Black and White Hypertensive Patients. <i>Hypertension</i> , 1995, 26, 124-130.	2.7	113
481	Supplementation of Immunosuppressive Regimens with Calcium Channel Blockers. <i>BioDrugs</i> , 1994, 2, 458-467.	0.7	4
482	VALUE OF IN VITRO CD4+ T HELPER CELL FUNCTION TEST FOR PREDICTING LONG-TERM LOSS OF HUMAN RENAL ALLOGRAFTS. <i>Transplantation</i> , 1994, 57, 480-482.	1.0	4
483	Renal adaptation to the failing heart. <i>Postgraduate Medicine</i> , 1994, 95, 153-156.	2.0	22
484	Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. <i>Immunopharmacology</i> , 1993, 25, 75-82.	2.0	11
485	Essential Hypertension in Blacks: Is It a Metabolic Disorder?. <i>American Journal of Kidney Diseases</i> , 1993, 21, 58-67.	1.9	7
486	Risk for renal injury in diabetic hypertensive patients. <i>Postgraduate Medicine</i> , 1992, 91, 77-84.	2.0	3

#	ARTICLE	IF	CITATIONS
487	Risk for renal injury in diabetic hypertensive patients. <i>Postgraduate Medicine</i> , 1992, 91, 87-95.	2.0	1
488	EVIDENCE THAT THE ANTIPROLIFERATIVE EFFECT OF VERAPAMIL ON AFFERENT AND EFFERENT IMMUNE RESPONSES IS INDEPENDENT OF CALCIUM CHANNEL INHIBITION. <i>Transplantation</i> , 1992, 54, 681-685.	1.0	19
489	A dose-response trial of once-daily diltiazem. <i>American Heart Journal</i> , 1992, 123, 1022-1026.	2.7	29
490	Determinants of the renal response to ACE inhibition in patients with congestive heart failure. <i>American Heart Journal</i> , 1992, 124, 131-136.	2.7	14
491	Hypertensive nephropathy: Is a more physiologic approach to blood pressure control an important concern for the preservation of renal function?. <i>American Journal of Medicine</i> , 1992, 93, S27-S37.	1.5	12
492	Impact of age, race, and obesity on hypertensive mechanisms and therapy. <i>American Journal of Medicine</i> , 1991, 90, S3-S14.	1.5	29
493	Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: Blood pressure control and immunosuppression. <i>American Journal of Medicine</i> , 1991, 90, S32-S36.	1.5	38
494	Minimization of Indomethacin-Induced Reduction in Renal Function by Misoprostol. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 729-735.	2.0	18
495	CORRELATION OF IN VITRO CD4+ T HELPER CELL FUNCTION WITH CLINICAL GRAFT STATUS IN IMMUNOSUPPRESSED KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1991, 52, 284-290.	1.0	44
496	ADDITIVE INHIBITION OF AFFERENT AND EFFERENT IMMUNOLOGICAL RESPONSES OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS BY VERAPAMIL AND CYCLOSPORINE. <i>Transplantation</i> , 1991, 51, 851-857.	1.0	21
497	ACUTE EFFECTS OF INTRAVENOUS CYCLOSPORINE ON BLOOD PRESSURE, RENAL HEMODYNAMICS, AND URINE PROSTAGLANDIN PRODUCTION OF HEALTHY HUMANS. <i>Transplantation</i> , 1990, 49, 41-47.	1.0	78
498	Evaluation of the Clinical Pharmacology of Nilvadipine in Patients with Mild to Moderate Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 425-437.	2.0	4
499	RADIX Tripterygium Wilfordii—A CHINESE HERBAL MEDICINE WITH POTENT IMMUNOSUPPRESSIVE PROPERTIES. <i>Transplantation</i> , 1990, 50, 82-85.	1.0	38
500	Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. <i>American Journal of Cardiology</i> , 1990, 66, D14-D21.	1.6	23
501	Preliminary Observations of the Acute Effects of Selective Serum Thromboxane Inhibition and Angiotensin Converting Enzyme Inhibition on Blood Pressure and Renal Hemodynamics in Hypertensive Humans. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 1108-1116.	2.0	1
502	RENAL ALLOGRAFT BIOPSY AND CONVERSION OF CYCLOSPORINE TO AZATHIOPRINE. <i>Transplantation</i> , 1989, 47, 223-228.	1.0	13
503	Pharmacologic management of systemic hypertension in blacks. <i>American Journal of Cardiology</i> , 1988, 61, H46-H52.	1.6	33
504	Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. <i>American Journal of Cardiology</i> , 1988, 61, H60-H66.	1.6	11



#	ARTICLE	IF	CITATIONS
505	INCIDENCE AND MORBIDITY OF CYTOMEGALOVIRUS DISEASE ASSOCIATED WITH A SERONEGATIVE RECIPIENT RECEIVING SEROPOSITIVE DONOR-SPECIFIC TRANSFUSION AND LIVING-RELATED DONOR TRANSPLANTATION. Transplantation, 1988, 45, 111-115.	1.0	27
506	INCIDENCE OF CYTOMEGALOVIRUS DISEASE IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTS BASED ON DONOR/RECIPIENT PRETRANSPLANT IMMUNITY. Transplantation, 1987, 43, 187-192.	1.0	36
507	Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. American Journal of Cardiology, 1987, 60, 36-41.	1.6	19
508	THE PROGNOSTIC VALUE OF THE EOSINOPHIL IN ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 1986, 41, 709-712.	1.0	63
509	REEVALUATION OF T CELL SUBSET MONITORING IN CYCLOSPORINE-TREATED RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1985, 40, 620-623.	1.0	16
510	ENZYME-LINKED IMMUNOSORBENT ASSAY FOR SERUM RENAL TUBULAR ANTIGEN IN KIDNEY TRANSPLANT PATIENTS. Transplantation, 1985, 40, 642-647.	1.0	2